Yeast vaginitis during pregnancy: Susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors

Medical Mycology

Volumn 50, Issue 6, 2012, Pages 585-593

  Kalkanci, Ayşe ^a   Güzel, Ahmet Bariş ^b   Khalil, Israa Ibrahim Jabban ^a   Aydin, Merve ^a   Ilkit, MacIt ^b   Kuştimur, Semra ^a  

^a GAZI UNIVERSITY   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Antifungal susceptibility; Candida albicans; Imidazoles; Phospholipase; Pregnancy; Proteinase

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; BORIC ACID; CASPOFUNGIN; CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; PHOSPHOLIPASE; PROTEINASE; SULCONAZOLE; TERBINAFINE; TIOCONAZOLE; VIRULENCE FACTOR;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CELL ADHESION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FUNGAL DETECTION; FUNGAL VIRULENCE; HEMOLYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREGNANCY COMPLICATION; RECURRENT DISEASE; SACCHAROMYCES CEREVISIAE; STATISTICAL SIGNIFICANCE; VAGINA CANDIDIASIS; VAGINA EPITHELIUM; VAGINA MYCOSIS; ADHESION; CANDIDA; FUNGUS ISOLATION; PREGNANCY; PREGNANT WOMAN; RECURRENT INFECTION;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BORIC ACIDS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS, VULVOVAGINAL; CELL ADHESION; EPITHELIAL CELLS; FEMALE; FLUCONAZOLE; FUNGAL PROTEINS; HEMOLYSIS; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHOSPHOLIPASES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RECURRENCE; SACCHAROMYCES CEREVISIAE; VAGINA; VIRULENCE FACTORS; YOUNG ADULT;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; SACCHAROMYCES CEREVISIAE;

EID: 84863887190     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2012.662597     Document Type: Article

References (44)

1. Sobel JD. Vulvovaginal candidosis. Lancet 2007; 3 69: 1961-1971.
2. Donders GGG, Bellen G, Mendling W. Management of recurrent vulvo-vaginal candidosis as chronic illness. Gynecol Obstet Invest 2010; 70: 306-321.
3. Ilkit M, G üzel AB. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: A mycological perspective. Crit Rev Microbiol 2011; 37: 250-261.
4. Robinson SC, Nicholas WC, Lee DT, Wanklin JM, Zwicker B. The relationship of pregnancy, vaginal candidiasis and glucose metabolism. Can Med Assoc J 1967; 96: 583-585.
5. Roberts CL, Morris JM, Rickard KR, e t al . Protocol for a randomised controlled trials of treatment of asymptomatic candidiasis for the prevention of preterm birth. BMC Preg Child 2011; 11: 19.
6. Benjamin DK Jr. First, do no harm. Pediatrics 2008; 1 21: 831-832.
7. Soong D, Einarson A. Vaginal yeast infections during pregnancy. Can Fam Phys 2009; 55: 255-256.
8. Owen MK, Clenney TL. Management of vaginitis. Am Fam Physician 2004; 70: 2125-2132.
9. Zio C. A practical guide to dermatological drug use in pregnancy. Skin Ther Lett 2006; 11: 1-4.
10. Federal Register. 1980; 44: 37434-37467.
11. Sobel JD, Zervos M, Reed BD, et al . Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: Clinical implications. Antimicrob Agents Chemother 2003; 47: 34-38.
12. Guzel AB, Ilkit M, Burgut R, Urunsak IF, Ozgunen FT. An evaluation of risk factors in pregnant women with Candida vaginitis and the diagnostic value of simultaneous vaginal and rectal sampling. Mycopathologia 2011; 171: 25-36.
13. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, approved standard M27-A3. Wayne, PA: Clinical and Laboratory tandards Institute, 2008.
14. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. The CLSI Subcommittee for Antifungal Susceptibility Testing. Wildtype MIC distributions, epidemiological cutoff values and speciesSpecific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13: 180-195.
15. Biasoli MS, Tosello ME, Luque AG, Magar óHM. Adherence, colonization and dissemination of Candida dubliniensis and other Candida species. Med Mycol 2010; 48: 291-297.
16. Luo G, Samaranayake LP, Yau JY. C andida species exhibit differential in vitro hemolytic activities. J Clin Microbiol 2001; 39: 2971-2974.
17. Rüchel R, Böning B, Borg M. Characterization of a secretory proteinase of Candida parapsilosis and evidence for the absence of the enzyme during infection in vitro . Infect Immun 1986; 53: 411-419.
18. Price MF, Wilkinson ID, Gentry LO. Plate method for detection of phospholipase activity in Candida albicans . Sabouradia 1982; 20: 7-14.
19. Lynch ME, Sobel JD. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J Med Vet Mycol 1994; 32: 267-274.
20. Ribeiro MA, Dietze R, Paula CR, Da Matta DA, Colombo AL. Susceptibility profi le of vaginal yeast isolates from Brazil. Mycopathologia 2000; 151: 5-10.
21. Otero L, Fleites A, Méndez FJ, Palacio V, V ázquez F. Susceptibility of Candida species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid. Eur J Clin Microbiol Infect Dis 1999; 18: 59-61.
22. Richter SS, Galask RP, Messer SA, e t al . Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 43: 2155-2162.
23. Gross NT, Arias ML, Moraga M, Baddasarow Y, Jarstrand C. Species distribution and susceptibility to azoles of vaginal yeasts isolated prostitutes. Infect Dis Obstet Gynecol 2007; 2007: 82412.
24. Ozcan SK, Budak F, Y ücesoy G, Susever S, Willke A. Prevalence, susceptibility profi le and proteinase production of yeast causing vulvovaginitis in Turkish women. APMIS 2006; 114: 139-145.
25. Bulik CC, Sobel JD, Nailor MD. Susceptibility profi le of vaginal isolates of Candida albicans prior to and following fl uconazole introduction- impact of two decades. Mycoses 2011; 54: 34-38.
26. Fan SR, Liu XP. In vitro fl uconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis. Mycoses 2011; 54: 501-505.
27. Candido RC, Toloi RT, Franceschini SA, Garcia FR, Minto ECM. In vitro activity of antimycotic agents determined by E-Test method against vaginal Candida species. Mycopathologia 1998; 144: 15-20.
28. Mathema B, Cross E, Dun E, e t al . Prevalence of vaginal colonization by drug-Resistant Candida species in college-Age women with previous exposure to over-The-Counter azole antifungals. Clin Infect Dis 2001; 33: E23-27.
29. Sobel JD, Vazquez JA. Symptomatic vulvovaginitis due to fl uconazoleresistant Candida albicans in a female who was not infected with human immunodefi ciency virus. Clin Infect Dis 1996; 22: 726-727.
30. Van Slike KK, Michel VP, Rein MF. Treatment of vulvovaginal candidiasis with boric acid powder. Am J Obstet Gynecol 1981; 141: 145-148.
31. Shubair M, Larsen B. Growth inhibition of C andida albicans and other medically important yeasts by vaginal contraceptive methods. Gynecol Obstet Invest 1990; 29: 67-70.
32. Sobel JD, Chaim W. Treatment of Torulopsis glabrata vaginitis: Retrospective review of boric acid therapy. Clin Infect Dis 1997; 24: 649-652.
33. Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: Use of topical boric acid and fl ucytosine. Am J Obstet Gynecol 2003; 189: 1297-1300.
34. Lian CH, Liu WD. Differential expression of C andida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis. Mycoses 2007; 50: 383-390.
35. Taylor BN, Staib P, Binder A, e t al . Profi le of C andida albicans - secreted aspartic proteinase elicited during vaginal infection. Infect Immun 2005; 73: 1828-1835.
36. Yildirim Z, Kilic N, Kalkanci A. Fluorometric determination of acid proteinase activity in Candida albicans strains from diabetic patients with vulvovaginal candidiasis. Mycoses 2011; 54: E463-467.
37. Kalkanci A, Bozdayi G, Biri A, Kustimur S. Distribution of secreted aspartyl proteinases using a polymerase chain reaction assay with SAP Specific primers in Candida albicans isolates. Folia Microbiol 2005; 50: 409-413.
38. Costa CR, Passos XS, Souza LKH, e t al . Differences in exoenzyme production and adherence ability of Candida spp. isolates from catheter, blood and oral cavity. Rev Inst Med Trop Sao Paulo 2010; 52: 139-143.
39. Tosun I, Aydin F, Kaklikkaya N, Erturk M. Induction of secretory aspartyl proteinase of Candida albicans by HIV-1 but not HSV-2 or some other microorganisms associated with vaginal environment. Mycopathologia 2005; 159: 213-218.
40. Sacrist án B, Blanco MT, Gal án-Ladero A, et al . Aspartyl proteinase, phospholipase, hemolytic activities and biofi lm production of Candida albicans isolated from bronchial aspirates of ICU patients. Med Mycol 2011; 49: 94-97.
41. Tsang CSP, Chu FCS, Leung WK, e t al . Phospholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with type 2 diabetes mellitus. J Med Microbiol 2007; 56: 1393-1398.
42. Zhu W, Filler SG. Interactions of C andida albicans with epithelial cells. Cell Microbiol 2010; 12: 273-282.
43. Paiva LC, Donatti L, Patussi EV, Svizdinski TI, Lopes-Consolaro ME. Scanning electron and confocal scanning laser microscopy imaging of the ultrastructure and viability of vaginal Candida albicans and non- albicans species adhered to an intrauterine contraceptive device. Microsc Microanal 2010; 16: 537-549.
44. Watanabe T, Takano M, Murakami M, et al . Characterization of a haemolytic factor from Candida albicans . Microbiology 1999; 145: 689-694.